Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

916 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.
Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K. Hubmann M, et al. Among authors: hiddemann w. Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. Epub 2014 May 9. Haematologica. 2014. PMID: 24816240 Free PMC article. Clinical Trial.
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: hiddemann w. J Clin Oncol. 2009 Jan 1;27(1):61-9. doi: 10.1200/JCO.2007.15.4245. Epub 2008 Dec 1. J Clin Oncol. 2009. PMID: 19047294 Clinical Trial.
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Fritsch S, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Hiddemann W, Spiekermann K. Schneider F, et al. Among authors: hiddemann w. Blood. 2009 May 21;113(21):5250-3. doi: 10.1182/blood-2008-09-172668. Epub 2009 Mar 11. Blood. 2009. PMID: 19279329 Free article.
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K. Dufour A, et al. Among authors: hiddemann w. J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038735
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
Stelljes M, Beelen DW, Braess J, Sauerland MC, Heinecke A, Berning B, Kolb HJ, Holler E, Schwerdtfeger R, Arnold R, Spiekermann K, Müller-Tidow C, Serve HL, Silling G, Hiddemann W, Berdel WE, Büchner T, Kienast J; German AML Cooperative Group (AMLCG). Stelljes M, et al. Among authors: hiddemann w. Haematologica. 2011 Jul;96(7):972-9. doi: 10.3324/haematol.2011.041004. Epub 2011 Apr 1. Haematologica. 2011. PMID: 21459795 Free PMC article. Clinical Trial.
Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K. Schneider F, et al. Among authors: hiddemann w. Ann Hematol. 2012 Jan;91(1):9-18. doi: 10.1007/s00277-011-1280-6. Epub 2011 Jul 9. Ann Hematol. 2012. PMID: 21744003
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group. Dufour A, et al. Among authors: hiddemann w. Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. Epub 2012 Feb 24. Ann Hematol. 2012. PMID: 22362118
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype.
Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, Mellert G, Zellmeier E, Kakadia PM, Bohlander SK, Feuring-Buske M, Buske C, Braess J, Heinecke A, Sauerland MC, Berdel WE, Büchner T, Wörmann BJ, Hiddemann W, Spiekermann K. Schneider F, et al. Among authors: hiddemann w. Blood. 2012 May 10;119(19):4383-6. doi: 10.1182/blood-2010-12-327072. Epub 2012 Feb 28. Blood. 2012. PMID: 22374696 Free article. Clinical Trial.
RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK. Greif PA, et al. Among authors: hiddemann w. Haematologica. 2012 Dec;97(12):1909-15. doi: 10.3324/haematol.2012.064667. Epub 2012 Jun 11. Haematologica. 2012. PMID: 22689681 Free PMC article.
916 results